摘要
目的探讨金水宝胶囊联合瑞舒伐他汀治疗经皮冠状动脉介入治疗(PCI)术后并发造影剂肾病的临床疗效及对患者白蛋白(Alb)、尿素氮(BUN)、血肌酐(SCr)水平的影响。方法选取沙河市人民医院2017年3月至2019年3月收治的PCI术后并发造影剂肾病患者92例,按奇偶数法分为观察组和对照组,各46例。两组患者均予水化治疗、碱化尿液治疗及口服瑞舒伐他汀钙片,观察组患者加服金水宝胶囊,均持续治疗2周。结果观察组总有效率为91.30%,显著高于对照组的73.91%(P<0.05);治疗后,观察组患者的C反应蛋白(CRP)、白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、BUN及SCr水平均显著低于对照组,Alb水平显著高于对照组(P<0.05);观察组与对照组不良反应发生率相当(15.22%比8.70%,χ^2=0.929,P>0.05)。结论金水宝胶囊联合瑞舒伐他汀治疗PCI术后并发造影剂肾病,能改善患者的血清炎性因子水平及肾功能指标。
Objective To study the effect of Jinshuibao Capsules combined with rosuvastatin on contrast-induced nephropathy after percutaneous coronary intervention( PCI) and the effects of albumin( Alb),urea nitrogen( BUN) and serum creatinine( SCr). Methods A total of 92 patients with contrast-induced nephropathy after PCI in Shahe People’s Hospital from March 2017 to March 2019 were selected and divided into the observation group and control group according to odd and even number method,46 cases in each group. The control group was treated with rosuvastatin,and the observation group was treated with Jinshuibao Capsules on this basis. Both groups were continuously treated for 2 weeks. Results The total effective rate of the observation group was 91. 30%,which was significantly higher than 73. 91% of the control group( P < 0. 05). After treatment,the C-reactive protein( CRP),interleukin 6( IL-6),tumor necrosis factor-α( TNF-α),BUN and SCr levels of the observation group were significantly lower than those of the control group,and the Alb level was significantly higher than the control group( P < 0. 05);the observation group and the control group had the same incidence of adverse reactions( 15. 22% vs. 8. 70%,χ^2 = 0. 929,P > 0. 05). Conclusion Jinshuibao Capsules combined with rosuvastatin in the treatment of contrast-induced nephropathy after PCI can improve the level of serum inflammatory factors and renal function of patients.
作者
王大鹏
闫红霞
周立宾
王世杰
WANG Dapeng;YAN Hongxia;ZHOU Libin;WANG Shijie(Shahe People′s Hospital,Xingtai,Hebei,China 054100;Xingtai Mining Bureau Hospital,Xingtai,Hebei,China 054000;Xingtai People′s Hospital,Xingtai,Hebei,China 054001)
出处
《中国药业》
CAS
2020年第16期90-92,共3页
China Pharmaceuticals
基金
河北省医学科学研究课题[20191704]。
关键词
瑞舒伐他汀
金水宝胶囊
经皮冠状动脉介入治疗
造影剂肾病
临床疗效
肾功能指标
rosuvastatin
Jinshuibao Capsules
percutaneous coronary intervention
contrast-induced nephropathy
clinical efficacy
renal function indicators
